Evidence map›Paper›PMID 40274555›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[Are antibiotics immunomodulators? An attempt to use vancomycin in the treatment of primary sclerosing cholangitis].

L P Guo, W R Wang, B M Wang, L Zhou

Abstract readEnglish Abstract
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

L P GuoDepartment of Gastroenterology, Tianjin Medical University General Hospital, Tianjin 300052, China.
W R WangDepartment of Gastroenterology, Tianjin Medical University General Hospital, Tianjin 300052, China.
B M WangDepartment of Gastroenterology, Tianjin Medical University General Hospital, Tianjin 300052, China.
L ZhouDepartment of Gastroenterology, Tianjin Medical University General Hospital, Tianjin 300052, China.

Funding

National Natural Science Foundation of China 81860109, 81470834
6 · The paper itself

Abstract

Primary sclerosing cholangitis (PSC) is a type of chronic idiopathic liver disease characterized by bile duct inflammation and concentric fibrosis. Currently, no drug therapy can change the natural progression of PSC. The mechanism by which PSC is accompanied by the occurrence of inflammatory bowel disease (IBD) is still unclear. Oral antibiotic therapy with vancomycin being the most widely used has been shown to be effective for PSC combined with IBD. This paper analyzes case reports and clinical studies on the use of vancomycin in PSC, with the aim of providing a reference for clinical therapy and in-depth exploration of novel therapeutic directions.

Indexed as

Anti-Bacterial AgentsCholangitis, SclerosingVancomycinHumansInflammatory Bowel DiseasesAnti-Bacterial AgentsVancomycin

Identifiers

PMID40274555
PMCPMC12899214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.